Back to Search
Start Over
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
- Source :
- Plus Company Updates. January 13, 2022
- Publication Year :
- 2022
-
Abstract
- CAMBRIDGE: Verve Therapeutics has issued the following news release: Verve Therapeutics, Inc., (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.689502327